Universität zu Köln

Nobili, F., Arbizu, J., Bouwman, F., Drzezga, A., Agosta, F., Nestor, P., Walker, Z. and Boccardi, M. (2018). European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain F-18-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. Eur. J. Neurol., 25 (10). S. 1201 - 1218. HOBOKEN: WILEY. ISSN 1468-1331

Full text not available from this repository.

Abstract

Background and purposeRecommendations for using fluorodeoxyglucose positron emission tomography (FDG-PET) to support the diagnosis of dementing neurodegenerative disorders are sparse and poorly structured. MethodsTwenty-one questions on diagnostic issues and on semi-automated analysis to assist visual reading were defined. Literature was reviewed to assess study design, risk of bias, inconsistency, imprecision, indirectness and effect size. Critical outcomes were sensitivity, specificity, accuracy, positive/negative predictive value, area under the receiver operating characteristic curve, and positive/negative likelihood ratio of FDG-PET in detecting the target conditions. Using the Delphi method, an expert panel voted for/against the use of FDG-PET based on published evidence and expert opinion. ResultsOf the 1435 papers, 58 papers provided proper quantitative assessment of test performance. The panel agreed on recommending FDG-PET for 14 questions: diagnosing mild cognitive impairment due to Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) or dementia with Lewy bodies (DLB); diagnosing atypical AD and pseudo-dementia; differentiating between AD and DLB, FTLD or vascular dementia, between DLB and FTLD, and between Parkinson's disease and progressive supranuclear palsy; suggesting underlying pathophysiology in corticobasal degeneration and progressive primary aphasia, and cortical dysfunction in Parkinson's disease; using semi-automated assessment to assist visual reading. Panellists did not support FDG-PET use for pre-clinical stages of neurodegenerative disorders, for amyotrophic lateral sclerosis and Huntington disease diagnoses, and for amyotrophic lateral sclerosis or Huntington-disease-related cognitive decline. ConclusionsDespite limited formal evidence, panellists deemed FDG-PET useful in the early and differential diagnosis of the main neurodegenerative disorders, and semi-automated assessment helpful to assist visual reading. These decisions are proposed as interim recommendations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Nobili, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Arbizu, J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Bouwman, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Drzezga, A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Agosta, F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Nestor, P. UNSPECIFIED UNSPECIFIED UNSPECIFIED Walker, Z. UNSPECIFIED UNSPECIFIED UNSPECIFIED Boccardi, M. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-170238
DOI:	10.1111/ene.13728
Journal or Publication Title:	Eur. J. Neurol.
Volume:	25
Number:	10
Page Range:	S. 1201 - 1218
Date:	2018
Publisher:	WILEY
Place of Publication:	HOBOKEN
ISSN:	1468-1331
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language AMYOTROPHIC-LATERAL-SCLEROSIS; PROGRESSIVE SUPRANUCLEAR PALSY; CEREBRAL GLUCOSE-METABOLISM; ALZHEIMERS-DISEASE; FDG-PET; LEWY BODIES; F-18-FDG PET; DIFFERENTIAL-DIAGNOSIS; FRONTOTEMPORAL DEMENTIA; NATIONAL INSTITUTE Multiple languages Clinical Neurology; Neurosciences Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/17023